Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1960 1
1961 1
1962 1
1972 1
1973 1
1974 1
1976 2
1977 2
1979 5
1980 3
1981 1
1982 1
1983 3
1984 1
1985 4
1986 6
1987 4
1988 8
1989 13
1990 12
1991 6
1992 15
1993 13
1994 17
1995 16
1996 23
1997 20
1998 23
1999 38
2000 39
2001 37
2002 28
2003 38
2004 34
2005 26
2006 14
2007 20
2008 19
2009 18
2010 17
2011 21
2012 7
2013 15
2014 20
2015 22
2016 16
2017 14
2018 14
2019 32
2020 48
2021 39
2022 44
2023 30
2024 27
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

839 results

Results by year

Filters applied: . Clear all
Page 1
[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.
Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, van Praet C, Bailly C, Önal B, Aksoy T, Merkx R, Schuster DM, Lee ST, Pandit-Taskar N, Fan AC, Allman P, Schmidt K, Tauchmanova L, Wheatcroft M, Behrenbruch C, Hayward CRW, Mulders P. Shuch B, et al. Among authors: bailly c. Lancet Oncol. 2024 Oct;25(10):1277-1287. doi: 10.1016/S1470-2045(24)00402-9. Epub 2024 Sep 10. Lancet Oncol. 2024. PMID: 39270701 Free article. Clinical Trial.
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Among authors: bailly c. Nat Med. 2023 Oct;29(10):2593-2601. doi: 10.1038/s41591-023-02572-5. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710005 Free PMC article. Clinical Trial.
[Ecteinascidin 743].
Lansiaux A, Bailly C. Lansiaux A, et al. Among authors: bailly c. Bull Cancer. 1999 Feb;86(2):139-41. Bull Cancer. 1999. PMID: 10094523 Free article. Review. French. No abstract available.
Immuno-PET for Clinical Theranostic Approaches.
Bailly C, Cléry PF, Faivre-Chauvet A, Bourgeois M, Guérard F, Haddad F, Barbet J, Chérel M, Kraeber-Bodéré F, Carlier T, Bodet-Milin C. Bailly C, et al. Int J Mol Sci. 2016 Dec 28;18(1):57. doi: 10.3390/ijms18010057. Int J Mol Sci. 2016. PMID: 28036044 Free PMC article. Review.
Highly cytotoxic benzo[c]pyrido[2,3,4-kl]acridines.
Chackal S, Facompré M, Houssin R, Goossens JF, Pommery N, Hénichart JP, Bailly C. Chackal S, et al. Among authors: bailly c. Bioorg Med Chem Lett. 2003 Mar 10;13(5):943-6. doi: 10.1016/s0960-894x(02)01066-1. Bioorg Med Chem Lett. 2003. PMID: 12617926
[Dolastatins].
Lansiaux A, Bailly C. Lansiaux A, et al. Among authors: bailly c. Bull Cancer. 1999 Nov;86(11):897-901. Bull Cancer. 1999. PMID: 10586105 Free article. French. No abstract available.
Radioimmunotherapy for Treatment of Acute Leukemia.
Bodet-Milin C, Kraeber-Bodéré F, Eugène T, Guérard F, Gaschet J, Bailly C, Mougin M, Bourgeois M, Faivre-Chauvet A, Chérel M, Chevallier P. Bodet-Milin C, et al. Among authors: bailly c. Semin Nucl Med. 2016 Mar;46(2):135-46. doi: 10.1053/j.semnuclmed.2015.10.007. Semin Nucl Med. 2016. PMID: 26897718 Review.
839 results